Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4871-4880 Newer>

The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
The Motley Fool May 29, 2008 Brian Orelli	Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific.
Chemistry World May 28, 2008 Mark Peplow	Cancer research gets collaborative funding boost In an effort to crack some of the biggest problems in cancer drug discovery, Cancer Research UK has launched a unique funding program that promises to help bridge the gap between fundamental research and big pharma pipelines.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool May 28, 2008 Brian Lawler	No Barrier to Deals Like This In the latest example of overlap between the pharmaceutical and consumer-health care industries, Barrier Therapeutics announces that it will package one of its lead prescription drugs with a shampoo sold by Procter & Gamble.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool May 28, 2008 Brian Lawler	Discovery's Costly Debt Delay Discovery Labs announces a new financing agreement, but it's an expensive arrangement.
The Motley Fool May 28, 2008 Brian Lawler	A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan.
The Motley Fool May 28, 2008 Brian Lawler	A Strange Novartis MS Drug Story Novartis gets approval for a drug with an interesting history.
The Motley Fool May 28, 2008 Brian Orelli	A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs.
<Older 4871-4880 Newer> Return to current articles.